Je was op zoek naar: kl (Lets - Engels)

kl.
kl.

(kl)
(kc)

klīrenss (kl))
clearance (cl)

kl (ml/min)
cl (ml/min)

krickenbecker seen - kl.
krickenbecker seen — kl.

kl nisk inform cija
clinical particulars

dzimums neietekmēja kl.
the cl was not impacted by gender.

nafo 2 j + 3 kl
nafo 2 j + 3 kl

kl nisk inform cija na
clinical particulars lo

kļūdu līmeņa (kl) amplitūda
2 % 5 % er < 2 % (below materiality) range in which the error rate (er) is situated

kl ir zemas saķeres seguma koeficients.
kl is the low-adhesion surface coefficient

kl ir zemas saķeres ceļa seguma koeficients.
kl is the low-adhesion surface coefficient.

nieru kl renss bija aptuveni 350 ml/ min.
the renal clearance was approximately 350 ml/ min.

vidējā minimālā vidējā maksimālā klinšainiem kl krastiem līdz
remember that, in most countries, the minimum age for driv-

ta u, t k kl nisk pieredze par olanzap na lietošanu
4 anticholinergic activity while olanzapine demonstrated anticholinergic activity in vitro, experience during the clinical trials revealed a low incidence of related events.

kh un kl mēra, kā noteikts šā pielikuma 2. papildinājumā.
kh and kl are measured as laid down in appendix 2 to this annex.

kl nisk pieredze par novomix 30 lietošanu gr tniec bas laik ir ierobežota.
there is limited clinical experience with novomix 30 in pregnancy.

placebo kontrol tos kl niskos p t jumos (6 – 12
31 dementia-related psychosis and/ or behavioural disturbances olanzapine is not approved for the treatment of dementia-related psychosis and/ or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident.

nov rota tikai neliela vai m reni izteikta olanzap na kl rensa palielin šan s.
only slight to moderate increase in olanzapine clearance has been observed.

t p c sieviet m b rna z d šanas period t kl niska lietošana nav ieteicama.
its clinical use, therefore, cannot be recommended in breast-feeding women.